title: [Evaluation of erythropoiesis under the influence of recombinant human erythropoietin (R-EPO) in dialyzed patients].
abstract: 5 deeply anemic (Hb less than 8 g/dl, Ht less than 25%) dialyzed patients with chronic renal failure were treated during four months with r-Epo. Blood cells morphological parameters were estimated using hematological autoanalyser Technicon H1. Satisfactory increase of the Hb levels and RBC counts were observed in 4 patients, in one the improvement was insignificant. We observed three types of response to r-Epo treatment: 1) macrocytic type, 2) hypochromic type, and 3) non-hypochromic type, without lasting macrocytosis. Our results suggest that type of erythropoiesis depends on other active biological substances (iron, folic acid, vit. B12) necessary for correcting erythropoiesis. r-Epo administration appeared to be a safe and effective method of anaemia treatment in dialyzed patients. Its administration eliminated blood transfusion for six months.
authors.affiliation: Kliniki Chorób Nerek Instytutu Chorób Wewnetrznych.
authors.forename: A
authors.initials: A
authors.lastname: Debska-Slizień
authors.forename: J
authors.initials: J
authors.lastname: Kabata
authors.forename: B
authors.initials: B
authors.lastname: Rutkowski
authors.forename: D
authors.initials: D
authors.lastname: Ciesielski
authors.forename: E
authors.initials: E
authors.lastname: Jankowska-Gan
authors.forename: A
authors.initials: A
authors.lastname: Manitius
mesh_terms: D000328:Adult; D000740:Anemia / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin
vernacular_title: Ocena odnowy układu czerwonokrwinkowego pod wpływem rekombinowanej erytropoetyny (r-Epo) u pacjentów dializowanych.